Related Experiment Video
Updated: Apr 19, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Use of antiplatelet drugs after cardiac operations
Victor A Ferraris1, Michael D Bolanos1
1Division of Cardiothoracic & Vascular Surgery, Chandler Medical Center, University of Kentucky, Lexington, Kentucky.
Insights
Dual antiplatelet therapy, including aspirin and clopidogrel, after coronary artery bypass graft (CABG) surgery appears to reduce early graft failure. This approach may improve outcomes compared to aspirin alone, though further research is needed.
Area of Science:
- Cardiovascular Surgery
- Pharmacology
- Clinical Evidence Review
Background:
- Venous bypass grafts are crucial for coronary artery bypass graft (CABG) surgery.
- Occlusive disease in venous grafts limits CABG effectiveness.
- Antiplatelet drugs are used post-CABG to mitigate graft occlusion.
Purpose of the Study:
- To review evidence on antiplatelet drug use after CABG.
- To identify controversies in antiplatelet therapy indications.
- To provide evidence-based recommendations for limiting graft occlusion.
Main Methods:
- Systematic review of relevant literature.
- Analysis of evidence regarding antiplatelet drug efficacy post-CABG.
- Identification of controversial issues and knowledge gaps.
Main Results:
- Dual antiplatelet therapy (aspirin and clopidogrel) post-CABG minimizes early graft failure (within 1 year).
- Dual therapy shows improved intermediate-term outcomes compared to aspirin alone.
- Evidence supporting these findings has limitations.
Conclusions:
- Dual antiplatelet therapy is suggested for most CABG patients to improve graft patency.
- Further clinical trials are necessary to confirm or refine recommendations.
- Optimal antiplatelet strategies following CABG require ongoing investigation.
Abstract:
Unfortunately, venous bypass grafts still have a prominent role in operative coronary revascularization (coronary artery bypass graft [CABG]). Venous grafts develop pathologically occlusive disease that limits the effectiveness of CABG, and antiplatelet drugs following operation may limit this problem. The types and indications of antiplatelet drugs following CABG generate some controversy in the recent literature. This review surveys relevant evidence about the use of antiplatelet drugs following CABG to identify the controversial issues, define appropriate questions, and attempt to provide evidence-based interventions that may be helpful in limiting graft occlusion after CABG. Evidence suggests that, in most CABG patients, dual antiplatelet drugs (aspirin and clopidogrel), given after operation, minimizes early (within 1 year) graft failure and improves intermediate-term outcomes, better than single antiplatelet therapy with aspirin alone. There are gaps in the knowledge base that supports this contention, and future clinical trials will likely augment or alter this recommendation.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:22Aneurysm IV: Nursing Management
01:27Peripheral Artery Disease III: Interprofessional Care
01:23Peripheral Artery Disease V: Postoperative Nursing Management